Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement / Intercell AG announces Q3 results and presents business update: All development programs on track - Profitability expected for full year 2007 - Very strong financial position - ...

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- quaterly report 19.11.2007 Vienna (Austria), November 19, 2007 - Today, vaccine company Intercell AG (VSE: ICLL) announced its financial results for the third quarter 2007, and presented an update on the Company´s development programs. All development programs fully on track Japanese Encephalitis: » Significant progress for leading prophylactic vaccine program on track for market approvals - Finalization of EMEA-MAA and US-BLA filing planned for December 2007 » Results of Phase II for the vaccine in children expected in early 2008 Hospital acquired infections: » S. aureus vaccine - Start of clinical Phase II trial (with Merck & Co., Inc.) expected within the next weeks » Pseudomonas vaccine - preparations for start of clinical Phase II/III trials in 2008 on track Hepatitis C: » Statistically significant viral load reduction and good safety profile for therapeutic vaccine in interim analysis - full study data expected for Q1 2008 » Further clinical program under co-development arrangement with Novartis likely to include IC31® IC31® & AIP®: » IC31® - Influenza vaccine: All individuals within Phase I study vaccinated - results expected for early 2008 » IC31® - Tuberculosis vaccine: Two further clinical trials with the Danish Statens Serum Institut (SSI) expected to start this year » Pneumococcus vaccine: Preparations for start of Phase I study in 2008 for novel protein-based vaccine on track Novartis alliance: » Transaction closed as announced in July - Total upfront contribution of EUR 270 m - Significant further milestones expected - 4.8 m shares issued to Novartis at a price of EUR 31.25 per share in September » Full implementation for improved Influenza vaccine and co-development in Hepatitis C started in Q4 2007 Strong financial position - Profitability expected for full year 2007 » EUR 6.5 m net loss for Q3 2007 compared to EUR 9.5 m in Q3 2006. This means a decrease of 31.2 percent » Increase of aggregate revenues - EUR 7.4 m in Q3 2007 compared to EUR 0.7 m in Q3 2006 » EUR 9.8 m R&D expenses in Q3 2007 - up 17.0 percent compared to Q3 2006 following progress of development programs » Strong cash position with EUR 218.6 m in liquid funds at September 30, 2007.Given already committed further payments, cash position at the end of 2007 expected to be approx. EUR 300 m » Full year 2007 expected to be profitable based on already confirmed licensing income. Growth in profitability expected for 2008 Management Board: » Management Board, with Gerd Zettlmeissl as Chief Executive Officer, Werner Lanthaler as Chief Financial Officer, and Alexander von Gabain as Chief Scientific Officer, appointed for a further three-year term. Thomas Lingelbach appointed as a new member of the Management Board as Chief Operating Officer end of announcement euro adhoc 19.11.2007 07:24:55 -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Lucia Malfent Head of Communications Tel. +43 1 20620-303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Börsen: Wiener Börse AG / official market

Das könnte Sie auch interessieren: